EASI

LEO Pharma Presents Late-Breaking Positive Phase 2a Efficacy and Safety Results of LEO 138559 in Moderate-to-Severe Atopic Dermatitis at the 2023 AAD Annual Meeting

Retrieved on: 
Saturday, March 18, 2023
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Conditional sentence, University, Leo Pharma, BV, Aes, COVID-19, American Academy, Atopic dermatitis, Development, Dermatology, MD, Patient, AAD, LEO, American Academy of Dermatology, Cytokine, Upper respiratory tract infection, Safety, Pharmaceutical industry, EASI

LEO Pharma A/S, a global leader in medical dermatology, today announced that a Phase 2a trial evaluating the efficacy and safety of investigational agent LEO 138559 in adults with moderate-to-severe atopic dermatitis met its primary endpoint.

Key Points: 
  • LEO Pharma A/S, a global leader in medical dermatology, today announced that a Phase 2a trial evaluating the efficacy and safety of investigational agent LEO 138559 in adults with moderate-to-severe atopic dermatitis met its primary endpoint.
  • Results were shared as one of two LEO Pharma late breaker oral presentations at the 2023 American Academy of Dermatology (AAD) Annual Meeting.1 LEO 138559 is an investigational agent and its efficacy and safety are subject to further larger trials.
  • LEO Pharma and argenx BV jointly developed LEO 138559 under an exclusive option and research agreement.
  • LEO Pharma obtained the license to LEO 138559 in 2022 and now assumes the responsibility to develop and commercialize LEO 138559 for inflammatory skin disorders, such as atopic dermatitis.

Connect Biopharma CBP-201 Atopic Dermatitis China Pivotal Study Showed Rapid Relief of Patient Symptoms

Retrieved on: 
Saturday, March 18, 2023
Health, Other Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Maintenance, Psoriasis Area and Severity Index, EASI, Week, Dermatology, American Academy, Atopic dermatitis, IGA, 2008 Giro d'Italia, Stage 1 to Stage 11, Patient, Itch, AD, Skin, Inflammation, Vaccine

Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma or the Company), a global clinical-stage biopharmaceutical company developing T cell-driven therapies to treat inflammatory diseases, announced that data from Stage 1 of the ongoing pivotal CBP-201 China trial in moderate-to-severe atopic dermatitis (AD) showed rapid relief from symptoms, as early as week one in some cases, and no efficacy plateau at Week 16.

Key Points: 
  • Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma or the Company), a global clinical-stage biopharmaceutical company developing T cell-driven therapies to treat inflammatory diseases, announced that data from Stage 1 of the ongoing pivotal CBP-201 China trial in moderate-to-severe atopic dermatitis (AD) showed rapid relief from symptoms, as early as week one in some cases, and no efficacy plateau at Week 16.
  • In the study “CBP-201, a next-generation IL-4Rα antibody, achieved all primary and secondary efficacy endpoints in the treatment of adults with moderate-to-severe atopic dermatitis (AD): A randomized, double-blind, pivotal trial in China (CBP-201-CN002),” researchers reported on results from Stage 1 of the pivotal China trial of CBP-201 in moderate-to-severe AD.
  • Patients on active therapy experienced rapid relief of symptoms, with a reduction in itch at Week 1 and significant improvement in all study endpoints by Week 4, which was sustained to Week 16.
  • “We are honored to have data from our two CBP-201 atopic dermatitis studies at the prestigious American Academy of Dermatology Annual Meeting, showing rapid and sustained relief,” said Zheng Wei, Ph.D., Co-founder and CEO of Connect Biopharma.

Connect Biopharma CBP-201 Atopic Dermatitis Global Phase 2b Data Showed Rapid and Sustained Improvement Across all Body Regions

Retrieved on: 
Friday, March 17, 2023
Oncology, Health, Hospitals, General Health, Clinical Trials, Pharmaceutical, Biotechnology, Week, EASI, Dermatology, Atopic dermatitis, American Academy, Head, Neck, Patient, AD, Inflammation, Vaccine

This is the first time CBP-201 AD improvements have been broken down by body regions and symptom subtypes.

Key Points: 
  • This is the first time CBP-201 AD improvements have been broken down by body regions and symptom subtypes.
  • In the abstract entitled “Rapid and Sustained Improvements with CBP-201 Across All Body Regions: Treatment of Atopic Dermatitis in a Phase 2b, Randomized, Double-blind, Placebo-controlled Trial (CBP-201-WW001),” researchers reported that CBP-201 demonstrated rapid improvement in AD as early as Week 2 and sustained at Week 16 across four body regions: head and neck, trunk, upper limbs and lower limbs, compared to placebo.
  • In addition to overall AD improvement across all four body regions, researchers also observed improvement for each classification of AD symptoms (signs): erythema, induration/papulation, lichenification and excoriation, within each body region.
  • “CBP 201 also showed good AD reductions in the head and neck region, which is often more difficult to treat.

Roivant Reports Positive Topline Results from ADORING 2 Atopic Dermatitis Phase 3 Trial of VTAMA® (tapinarof) Cream, 1% Once Daily in Adults and Children as Young as 2 Years Old

Retrieved on: 
Wednesday, March 15, 2023
Linda, 2020 Henry Ford Health System 200, Adolescence, Pediatrics, Quality of life, Atopic dermatitis, Itch, Psoriasis, BSA, Clinical research, Dermatitis, Body surface area, Roivant Sciences, Patient, Rady, Physician, FDA, Pharmacist, Diagnosis, Prescription, JD, Week, Plaque, Surveying, Pharmaceutical industry, Cosmetics, Dietary supplement, EASI, MD, Dermatology

“Atopic dermatitis, the most common type of eczema, affects more than 9.6 million children and 16.5 million adults in the United States.

Key Points: 
  • “Atopic dermatitis, the most common type of eczema, affects more than 9.6 million children and 16.5 million adults in the United States.
  • In the U.S., VTAMA cream is already approved for the topical treatment of plaque psoriasis in adults.
  • Importantly, VTAMA cream data indicated no safety or tolerability signals in this population including children as young as 2 years old.
  • “Atopic dermatitis can have a negative impact on the quality of life of diagnosed children as well as their families.

Dermavant Reports Positive Topline Results from ADORING 2 Atopic Dermatitis Phase 3 Trial of VTAMA® (tapinarof) Cream, 1% Once Daily in Adults and Children as Young as 2 Years Old

Retrieved on: 
Wednesday, March 15, 2023
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Linda, 2020 Henry Ford Health System 200, Adolescence, Pediatrics, Quality of life, Common, Atopic dermatitis, Itch, Psoriasis, Stinger, Swelling, BSA, Irritation, Clinical research, Dermatitis, Body surface area, Nose, Patient, Roivant Sciences, Rady, Physician, Pain, FDA, Pharmacist, Diagnosis, Prescription, JD, Week, Rash, Folliculitis, Incidence, Headache, Plaque, Surveying, Pharmaceutical industry, Cosmetics, Dietary supplement, EASI, MD, Dermatology

“Atopic dermatitis, the most common type of eczema, affects more than 9.6 million children and 16.5 million adults in the United States.

Key Points: 
  • “Atopic dermatitis, the most common type of eczema, affects more than 9.6 million children and 16.5 million adults in the United States.
  • In the U.S., VTAMA cream is already approved for the topical treatment of plaque psoriasis in adults.
  • Importantly, VTAMA cream data indicated no safety or tolerability signals in this population including children as young as 2 years old.
  • “Atopic dermatitis can have a negative impact on the quality of life of diagnosed children as well as their families.

AbbVie Showcases Strength of Dermatology Portfolio with New Data Presented at the 2023 AAD Annual Meeting

Retrieved on: 
Monday, March 13, 2023
Abstract, NORTH, AAD, Research, Psoriasis, NYSE, ABBV, Atopic dermatitis, Itch, Head, AbbVie, Quality of life, American Academy, Dermatology, Patient, Hidradenitis suppurativa, Safety, Sleep, EASI, Risankizumab, Pharmaceutical industry

NORTH CHICAGO, Ill., March 13, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced it will present more than 20 abstracts, including one late-breaking presentation during the 2023 American Academy of Dermatology (AAD) Annual Meeting, March 17-21, in New Orleans, Louisiana.  

Key Points: 
  • "The data at this year's AAD conference demonstrate AbbVie's commitment to investing in its dermatology portfolio to further improve outcomes for patients with immune-mediated skin conditions," said Celine Goldberger, M.D., vice president, head of U.S. medical affairs, AbbVie.
  • The oral and poster presentations from AbbVie highlight research across the company's collective portfolio, further demonstrating leadership in dermatology innovation.
  • Data feature outcomes in psoriatic disease, atopic dermatitis and hidradenitis suppurativa to support patients living with immune-mediated skin conditions.
  • The 2023 AAD Annual Meeting e-Posters are available here and late-breaking sessions are available here .

ASLAN Pharmaceuticals Announces Completion of Recruitment in Phase 2b TREK-AD Study of Eblasakimab in Atopic Dermatitis Patients

Retrieved on: 
Friday, February 24, 2023
Safety, CMO, Patient, SAN, ASLN, AD, Physician, Pharmaceutical industry, EASI

ASLAN expects to report topline data from this study in early July 2023.

Key Points: 
  • ASLAN expects to report topline data from this study in early July 2023.
  • The randomized, double-blind, placebo-controlled, dose-ranging clinical study, TREK-AD, was initiated in early 2022 to evaluate the efficacy and safety of eblasakimab in biologic naïve AD patients during a 16-week treatment period and a 12-week safety follow-up period.
  • The study has enrolled patients from more than 80 sites across North America, Europe and Asia Pacific.
  • “We are grateful to all patients, physicians, and trial investigators involved in the study.

Evelo Biosciences Provides Clinical and Business Updates

Retrieved on: 
Wednesday, February 1, 2023
Prevalence, Geography, Food, Psoriasis Area and Severity Index, Patient, Science, EV, Trial of the century, Webcast, Medicines and Healthcare products Regulatory Agency, European Medicines Agency, Atopic dermatitis, EASI, Partnership, Clinical trial, Health care, FDA, Psoriasis, Phase 3, EMA, Workforce, Medication, MHRA, Medical imaging, Vaccine, Management, Silviculture, Pharmaceutical industry

CAMBRIDGE, Mass., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a novel platform of orally delivered medicines acting on the small intestinal axis (SINTAX) today announced updates to its clinical pipeline as well as business updates.

Key Points: 
  • ET –
    CAMBRIDGE, Mass., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a novel platform of orally delivered medicines acting on the small intestinal axis (SINTAX) today announced updates to its clinical pipeline as well as business updates.
  • Based on their feedback, we believe we have a clear path towards a global registration program for EDP1815 in psoriasis.
  • As part of this initiative, we have reduced our workforce and are prioritizing investment in our core clinical programs.
  • Evelo is in active discussions regarding partnership opportunities across EDP1815, EDP2939, as well as the EV platform.

ASLAN Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Friday, October 28, 2022
Â, Clinical trial, ESDR, American depositary receipt, AD, Development, European Society for Medical Oncology, Feinberg School of Medicine, Itch, Safety, Nasdaq, B cell, CEO, European Academy of Microbiology, ADS, Patient, Research, Technology, EASI, News, GLOBE, Trial, Johns Hopkins University, SAN, Eosinophil, Investment, New York Public Library, ASLN, Congress, Sleep, Investor relations, Biomarker, Pharmaceutical industry, Cryptocurrency, Company, Dupilumab, Venereology, Dermatology

Cash used in operating activities for the third quarter of 2022 was US$9.1 million compared to US$7.6 million in the same period in 2021.

Key Points: 
  • Cash used in operating activities for the third quarter of 2022 was US$9.1 million compared to US$7.6 million in the same period in 2021.
  • Research and development expenses were US$8.0 million in the third quarter of 2022 compared to US$5.3 million in the third quarter of 2021.
  • General and administrative expenses were US$2.3 million in the third quarter of 2022 compared to US$2.8 million in the third quarter of 2021.
  • Net loss attributable to stockholders for the third quarter of 2022 was US$10.9 million compared to a net loss of US$8.6 million for the third quarter of 2021.